Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis

被引:40
作者
Sugimoto, Mitsushige [1 ]
Murata, Masaki [2 ]
Yamaoka, Yoshio [3 ]
机构
[1] Tokyo Med Univ Hosp, Dept Gastroenterol Endoscopy, Sinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 600023, Japan
[2] Natl Hosp Org, Dept Gastroenterol, Kyoto Med Ctr, Kyoto 618555, Japan
[3] Oita Univ, Dept Gastroenterol, Dept Environm & Prevent Med, Fac Med, Oita 879559, Japan
关键词
Helicobacter pylori; Eradication therapy; Gastric cancer; Metachronous cancer; East Asia; Prevention; ENDOSCOPIC SUBMUCOSAL DISSECTION; RANDOMIZED CLINICAL-TRIAL; PEPTIC-ULCER; INTESTINAL METAPLASIA; HIGH-RISK; JAPANESE PATIENTS; DUODENAL-ULCER; OPEN-LABEL; RESECTION; INFECTION;
D O I
10.3748/wjg.v26.i15.1820
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Helicobacter pylori (H. pylori) infection is a risk factor for gastric cancer (GC), especially in East Asian populations. Most East Asian populations infected with H. pylori are at higher risk for GC than H. pylori-positive European and United States populations. H. pylori eradication therapy reduces gastric cancer risk in patients after endoscopic and operative resection for GC, as well as in non-GC patients with atrophic gastritis. AIM To clarify the chemopreventive effects of H. pylori eradication therapy in an East Asian population with a high incidence of GC. METHODS PubMed and the Cochrane library were searched for randomized control trials (RCTs) and cohort studies published in English up to March 2019. Subgroup analyses were conducted with regard to study designs (i.e., RCTs or cohort studies), country where the study was conducted (i.e., Japan, China, and South Korea), and observation periods (i.e., <= 5 years and > 5 years). The heterogeneity and publication bias were also measured. RESULTS For non-GC patients with atrophic gastritis and patients after resection for GC, 4 and 4 RCTs and 12 and 18 cohort studies were included, respectively. In RCTs, the median incidence of GC for the untreated control groups and the treatment groups was 272.7 (180.4-322.4) and 162.3 (72.5-588.2) per 100000 person-years in non-GC cases with atrophic gastritis and 1790.7 (406.5-2941.2) and 1126.2 (678.7-1223.1) per 100000 person-years in cases of after resection for GC. Compared with non-treated H. pylori-positive controls, the eradication groups had a significantly reduced risk of GC, with a relative risk of 0.67 [95% confidence interval (CI): 0.47-0.96] for non-GC patients with atrophic gastritis and 0.51 (0.36-0.73) for patients after resection for GC in the RCTs, and 0.39 (0.30-0.51) for patients with gastritis and 0.54 (0.44-0.67) for patients after resection in cohort studies. CONCLUSION In the East Asian population with a high risk of GC, H. pylori eradication effectively reduced the risk of GC, irrespective of past history of previous cancer.
引用
收藏
页码:1820 / 1840
页数:21
相关论文
共 94 条
[71]  
SUGIMOTO Y, 2012, DIAGN THER ENDOSC, V120
[72]   Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer [J].
Suzuki, S ;
Muroishi, Y ;
Nakanishi, I ;
Oda, Y .
JOURNAL OF GASTROENTEROLOGY, 2004, 39 (03) :220-230
[73]   Cancer statistics in Japan '03; Cancer incidence, rates and age-specific rates per 100,000 population in Japan according to sex and site [J].
Take, S ;
Mizuno, M ;
Ishiki, K ;
Nagahara, Y ;
Yoshida, T ;
Yokota, K ;
Oguma, K ;
Okada, H ;
Shiratori, Y .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05) :1037-1042
[74]   Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases [J].
Take, Susumu ;
Mizuno, Motowo ;
Ishiki, Kuniharu ;
Nagahara, Yasuhiro ;
Yoshida, Tomowo ;
Yokota, Kenji ;
Oguma, Keiji .
JOURNAL OF GASTROENTEROLOGY, 2007, 42 (Suppl 17) :21-27
[75]   Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study [J].
Take, Susumu ;
Mizuno, Motowo ;
Ishiki, Kuniharu ;
Hamada, Fumihiro ;
Yoshida, Tomowo ;
Yokota, Kenji ;
Okada, Hiroyuki ;
Yamamoto, Kazuhide .
JOURNAL OF GASTROENTEROLOGY, 2015, 50 (06) :638-644
[76]   The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori [J].
Take, Susumu ;
Mizuno, Motowo ;
Ishiki, Kuniharu ;
Yoshida, Tomowo ;
Ohara, Nobuya ;
Yokota, Kenji ;
Oguma, Keiji ;
Okada, Hiroyuki ;
Yamamoto, Kazuhide .
JOURNAL OF GASTROENTEROLOGY, 2011, 46 (03) :318-324
[77]   Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type [J].
Takenaka, R. ;
Okada, H. ;
Kato, J. ;
Makidono, C. ;
Hori, S. ;
Kawahara, Y. ;
Miyoshi, M. ;
Yumoto, E. ;
Imagawa, A. ;
Toyokawa, T. ;
Sakaguchi, K. ;
Shiratori, Y. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (07) :805-812
[78]   Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan [J].
Tsuda, Momoko ;
Asaka, Masahiro ;
Kato, Mototsugu ;
Matsushima, Rumiko ;
Fujimori, Kenji ;
Akino, Kozo ;
Kikuchi, Shogo ;
Lin, Yingsong ;
Sakamoto, Naoya .
HELICOBACTER, 2017, 22 (05)
[79]   Helicobacter pylori infection and the development of gastric cancer. [J].
Uemura, N ;
Okamoto, S ;
Yamamoto, S ;
Matsumura, N ;
Yamaguchi, S ;
Yamakido, M ;
Taniyama, K ;
Sasaki, N ;
Schlemper, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (11) :784-789
[80]  
Uemura N, 1997, CANCER EPIDEM BIOMAR, V6, P639